2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 589

DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Abstract Number: 99

DC-Hil+ Myeloid-Derived Suppressor Cells Are Elevated in the Peripheral Blood and Lesional Skin of Cutaneous Lupus Patients
Abstract Number: 2948

Deconstructing the in Situ Myeloid Cell Microenvironment in Human Lupus Nephritis Tissue
Abstract Number: 78

Decreased B Cell Ataxia-Telangiectasia Mutated Expression and Receptor Diversity Identify a Subset of Rheumatoid Arthritis Patients with Increased Joint Erosion Prevalence
Abstract Number: 1392

Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Abstract Number: 1447

Decreased Lymphatic Drainage in the Hands of Flaring RA Patients As Measured By Indocyanine Green Clearance Via Real Time Near Infrared Imaging
Abstract Number: 176

Deductive Anatomy By Self-Examination. a Novel Method to Reinforce Traditional Teaching of Musculoskeletal Anatomy
Abstract Number: 175

Deductive Anatomy By Self-Examination. Preliminary Evaluation of a Novel Method to Reinforce Knowledge of Musculoskeletal Anatomy at the 2018 Panlar Meeting
Abstract Number: 149

Deep Immune-Profiling of CD4+ T Cells in Behçet’s Disease
Abstract Number: 2426

Defining a Standardized Core Data Set for Pregnancy Registers in Rheumatic Diseases – an European Approach
Abstract Number: 2182

Defining Alendronate Drug Holidays and Re-Initiation in US Medicare Data
Abstract Number: 1845

Defining and Examining Retention in Care in an Urban Lupus Cohort
Abstract Number: 2258

Defining Characteristics of Patients with Overlap between Sarcoidosis and Connective Tissue Diseases
Abstract Number: 965

Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436 Patients
Abstract Number: 1918

Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].